Regenxbio
RGNX
188 hedge funds and large institutions have $896M invested in Regenxbio in 2024 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 60 increasing their positions, 53 reducing their positions, and 23 closing their positions.
74% more call options, than puts
Call options by funds: $2.37M | Put options by funds: $1.36M
74% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 23
25% more capital invested
Capital invested by funds: $717M → $896M (+$179M)
13% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 53
10% more funds holding
Funds holding: 171 → 188 (+17)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.87% less ownership
Funds ownership: 90.8% → 86.93% (-3.9%)
Top Buyers
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$23.1M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$14.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.76M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$7.74M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$40.9M |
| 2 |
BlackRock
New York
|
-$10.8M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$7.17M |
| 4 |
PA
Perceptive Advisors
New York
|
-$6.15M |
| 5 |
JP Morgan Chase
New York
|
-$3.86M |
RGNX Hedge Fund Activity: Q1 2024 in Review
188 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q1 2024, worth a combined $896M — up 25% from $717M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new RGNX positions and 23 closed out — a net gain of 17 holders — while 60 added to existing stakes and 53 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $23.1M. The largest seller was Morgan Stanley, cutting an estimated $40.9M.
- 188 institutional investors held Regenxbio (RGNX) as of Q1 2024, up from 171 in Q4 2023.
- Funds reported $896M of Regenxbio stock for Q1 2024, up 25% quarter-over-quarter.
- 40 funds opened new Regenxbio positions in Q1 2024 and 23 closed out, a net change of +17 holders.
- The largest Regenxbio buyer in Q1 2024 was Avidity Partners Management, an estimated $23.1M added.
- The largest Regenxbio seller in Q1 2024 was Morgan Stanley, an estimated $40.9M sold.
Based on aggregated 13F filings for Q1 2024.